How to Ask Fewer, Better Questions in Appointments

Focusing on what matters most to you—without feeling you’re wasting time

Many patients and carers worry about “asking too much” in clinic. Appointments are short, clinicians are busy, and you may already have a long list of questions in your head. The aim isn’t to stop asking questions—it’s to ask the right ones, at the right time, in the right way.

Here are practical strategies that help you stay focused, feel heard, and make the most of limited time.

1. Decide your Top 3 priorities before you go

Before the appointment, write down everything you’re thinking about. Then circle just three things that matter most right now.

Good priorities are usually:

  • A symptom that is new, worsening, or frightening

  • A treatment issue that affects daily life (side-effects, adherence, cost, function)

  • A decision you need to make soon

If it doesn’t change what happens in the next few weeks, it may not need airtime today.

If you remember only one thing: appointments are for decisions, not encyclopaedias.

2. Separate “need to know” from “nice to know”

It’s easy to mix curiosity with urgency.

Need to know (ask now):

  • Is this symptom important?

  • Is this treatment still right for me?

  • What should I do if X happens?

  • Are we monitoring the right things?

Nice to know (park for later):

  • Mechanisms, pathways, emerging research

  • Rare side-effects without symptoms

  • “What if” scenarios far in the future

Keep a “parking list” for later reading or discussion.

3. Frame questions around impact, not theory

Clinicians work best when questions are grounded in real life.

Instead of:

  • “I read a paper saying X might affect Y…”

Try:

  • “I’m noticing X in daily life—does that change what we do?”

  • “Is this symptom something you’d want to investigate?”

This signals relevance and helps clinicians triage quickly.

4. Ask one question at a time

Long, multi-part questions feel overwhelming and are easy to partially answer.

Break them down:

  • First: Is this important?

  • Then (if yes): What do we do about it?

  • Then (if needed): What should I watch for?

You’ll often find later questions become unnecessary once the first is answered.

5. Use the “Is this something we should…” test

This single phrase keeps questions concise and respectful of time:

  • “Is this something we should investigate?”

  • “Is this something that changes treatment?”

  • “Is this something I should worry about?”

A clear yes/no (or not yet) is often all you need.

6. Accept that not everything fits in one appointment

It’s okay—and normal—to say:

  • “I know we may not have time today—what should I prioritise?”

  • “Which of these matters most from your point of view?”

This shows partnership, not passivity.

If something needs more time, ask how best to handle it:

  • Another appointment

  • A nurse specialist

  • Written advice

  • Monitoring and review later

7. Bring written notes (but don’t read them all out)

A short list helps you stay focused under pressure.

Tip:

  • Highlight your top 3

  • Tick them off as they’re addressed

  • If time runs out, you still covered what mattered most

8. For carers: ask on behalf, not over

Carers often worry about dominating the conversation.

Helpful approaches:

  • Ask the patient first: “What do you most want answered today?”

  • Step in only if something important is being missed

  • Offer to follow up questions outside the appointment if possible

9. Reassure yourself: clinicians don’t expect perfection

You are not expected to:

  • Understand everything

  • Ask the “right” questions every time

  • Cover your entire condition in one visit

Good clinicians prefer:

a focused conversation
over
a rushed, overloaded one

10. A simple closing question that saves time

If time is tight, end with:

  • “Is there anything you think I should have asked but didn’t?”

This often surfaces the most important point of all.

The takeaway

You are not wasting time by asking questions—you’re wasting time by asking too many unfocused ones.

Clarity, prioritisation, and relevance help everyone:

  • You leave with answers that matter

  • Clinicians can make better decisions

  • Anxiety is reduced, not fuelled

by GAtherton

Learning About Aspergillosis (and Related Treatments)

How to stay curious, informed, and safe — without overload

Many people living with aspergillosis, or caring for someone who is, become highly motivated learners. You may read scientific papers, books, online articles, social media posts, AI summaries, and news stories about antifungal treatments, steroids, biologics, side-effects, immunity, mould exposure, diet, exercise, and wellbeing.

That curiosity is a strength. It helps you ask better questions, notice changes early, and feel more involved in your care.

At the same time, not all information is reliable, relevant, or helpful, and even good information can become harmful if it is over-interpreted or taken out of context. This article is about finding the balance: learning with confidence, without increasing anxiety or risk.

Why learning helps — and why it can sometimes backfire

The positives

  • Empowerment: Understanding your condition improves confidence.

  • Better conversations: Appointments are more productive when you share a common language.

  • Early awareness: You may recognise symptoms or side-effects sooner.

  • Reassurance: Knowledge can reduce uncertainty and fear.

The risks

  • Over-interpretation: A single paper or post can feel more important than it is.

  • Variable quality: Some research is weak, outdated, biased, or misapplied.

  • Loss of context: Lab studies or rare case reports may not apply to you.

  • Rising anxiety: Constant searching can amplify worry rather than reduce it.

  • Information overload: Too much input can make decisions harder, not easier.

A healthier approach to learning

1. Think in weight of evidence, not single findings

One article, story, or AI answer almost never changes medical care on its own.

When you read something new, ask:

  • Is this supported by more than one study?

  • Does it appear in guidelines or specialist practice?

  • Is it discussed cautiously, or presented as a breakthrough?

A useful rule of thumb:

The more dramatic the claim, the stronger the evidence needs to be.

2. Separate biological possibility from clinical reality

Many things are biologically plausible — immune pathways, hormones, inflammation, the microbiome — but that doesn’t mean they are proven or clinically relevant.

Helpful questions include:

  • Was this studied in people, or only in the lab?

  • Were the patients similar to me?

  • Did it improve symptoms or outcomes, not just blood tests?

Choosing trusted health information: practical guidance

Learning safely isn’t about reading less. It’s about choosing better sources and knowing how much weight to give them.

3. Start with sources that anchor practice

Your most reliable foundations are sources that:

  • Reflect clinical consensus, not speculation

  • Are written or reviewed by specialist teams

  • Change slowly because they are evidence-based

Examples include:

  • Specialist centre or hospital websites

  • National or international guidelines

  • Established patient organisations linked to clinical services

Examples:

    • NHS website
      A good starting point for clear, balanced information on symptoms, tests, treatments, and general health advice.
      Useful for understanding what is considered standard care in the UK.

    • British National Formulary (BNF)
      The main UK reference for medicines.
      Particularly helpful for:

      • Medication side-effects

      • Drug interactions (including antifungals, steroids, and inhalers)

      • Practical prescribing information
        Side-effects are listed cautiously, so not everything applies to every person.

    • aspergillosis.org
      A specialist resource focused specifically on aspergillosis, written for patients, carers, and professionals.
      Helpful for understanding different forms of aspergillosis, investigations, treatments, and living with the condition.

    • European Lung Foundation – Aspergillosis resources
      Patient-focused information developed with respiratory specialists and patient representatives across Europe.
      Particularly useful for:

      • Plain-language explanations

      • Patient priorities and lived experience

      • Shared decision-making and questions to ask in clinic

    • Asthma + Lung UK (BLF)
      A trusted source for asthma and other lung diseases.
      Helpful for inhaler use, breathlessness, flare-ups, lifestyle advice, and living well with chronic lung conditions.

    • Aspergillosis Trust
      This website was created by patients who suffer from Aspergillosis. Please navigate around the website to read more about this disease, also the impact it has upon patients and their carers.

These sources may feel less exciting — but they set the safe boundaries of what is known.

4. Learn to spot interpretation versus evidence

Two people can read the same paper and draw very different conclusions.

Ask yourself:

  • Is this source presenting evidence, or interpreting it strongly?

  • Are limitations and uncertainty acknowledged?

  • Is the language careful or absolute?

Trusted sources often say:

“Evidence suggests…” or “We don’t yet know…”

Less reliable ones often say:

“This proves…” or “This explains everything.”

5. Use a simple credibility checklist

You don’t need to be a scientist to judge quality.

When reading anything, consider:

Who wrote it?
Clinical specialists, recognised organisations, or anonymous individuals?

Why was it written?
To inform and support — or to sell, persuade, or provoke?

What evidence is used?
Multiple studies and guidelines — or a single paper or personal story?

What tone is used?
Balanced and cautious — or dramatic and fear-based?

Several warning signs together should lower confidence.

6. Be cautious with “hidden” or “overlooked” explanations

Phrases that should trigger caution include:

  • “Doctors don’t tell you this…”

  • “The hidden cause…”

  • “The real reason…”

  • “One simple explanation…”

Conditions like aspergillosis are complex. Simple, universal explanations are rarely accurate.

7. Understand where research sits on the evidence ladder

Not all research carries the same weight.

Very roughly:

  1. Clinical guidelines and consensus statements

  2. Large clinical trials and systematic reviews

  3. Observational studies

  4. Case reports

  5. Laboratory or animal studies

  6. Opinions and anecdotes

Lower down the ladder does not mean “worthless” — but it does mean less certain and less likely to change care on its own.

8. Treat patient stories and forums as experience, not prediction

Patient experiences are invaluable for:

  • Feeling less alone

  • Understanding day-to-day challenges

  • Sharing coping strategies

They are not reliable predictors of:

  • What will happen to you

  • How common a problem is

  • Whether a treatment will help or harm you

A helpful distinction:

Stories help you feel understood. Evidence helps guide decisions.

9. Use AI tools wisely

AI can be excellent for:

  • Explaining terminology

  • Summarising broad topics

  • Helping you generate questions

AI cannot:

  • Replace specialist judgement

  • Fully understand your medical history

  • Balance risk in the way clinicians do

Treat AI as:

“A map to the topic,”
not
“An answer about me.”

10. Limit your sources — and give yourself permission to stop

Many people feel calmer once they:

  • Choose two to four trusted sources

  • Revisit those instead of endlessly searching

  • Accept that not every new paper needs action

Stopping is not giving up — it is protecting your wellbeing.

Bringing what you’ve learned into clinic

A good sign you’ve chosen reliable information:

  • You feel comfortable sharing it with clinicians

  • It leads to discussion, not confusion

  • It helps prioritise decisions

You might say:

  • “I’ve been reading from a specialist source — how relevant is this to me?”

  • “This helped me understand X, but I’m not sure how much weight to give it.”

When to pause or rebalance your learning

Consider stepping back if:

  • Searching increases anxiety every time

  • You feel pressure to solve everything yourself

  • Conflicting information leaves you stuck

  • Illness becomes the only thing you think about

Taking breaks from research is not disengagement — it is self-care.

The key message

Learning is a powerful tool. Used well, it supports confidence, partnership, and resilience. Used without guardrails, it can undermine peace of mind.

Aim for:

  • Curiosity with caution

  • Knowledge with context

  • Questions with balance

You don’t need to know everything.
You need to know what helps you live well and safely.

This article pairs with:
“Making the Most of Appointments: Asking Fewer, Better Questions” — a practical guide to deciding what to raise in clinic and how to use limited time effectively.

by GAtherton

Aspergillus Updates week 51

1. Immunodeficiency, rare syndromes & aspergillosis risk

Standing Still: A Case of Stiff Person Syndrome and Common Variable Immunodeficiency

Khazar et al., Cureus, 2025

Summary

  • Describes a rare coexistence of Stiff Person Syndrome (SPS) and Common Variable Immunodeficiency (CVID).

  • Highlights autoimmune–immunodeficiency overlap and diagnostic complexity.

Why it matters

  • CVID is a recognised risk factor for recurrent infections and chronic lung disease, including bronchiectasis and chronic pulmonary aspergillosis (CPA).

  • Reinforces the need for multisystem thinking when patients present with neurological and respiratory symptoms.

Limitations

  • Single case; no fungal infection reported.

  • Indirect relevance to aspergillosis but important for risk stratification.

Beyond Cystic Fibrosis: Recognising Shwachman–Diamond Syndrome in the Respiratory Clinic

Yang et al., Respirology Case Reports, 2025

Summary

  • Emphasises misdiagnosis of Shwachman–Diamond syndrome (SDS) as cystic fibrosis.

  • Includes discussion of allergic bronchopulmonary aspergillosis (ABPA) in the differential.

Why it matters

  • Reinforces that non-CF genetic syndromes can present with:

    • Bronchiectasis

    • Recurrent infection

    • ABPA-like features

  • Highly relevant to adult respiratory clinics and late diagnoses.

Clinical takeaway

  • ABPA should prompt consideration of underlying immune or genetic disease, not just asthma or CF.

2. Genetics & structural lung disease

Exome sequencing reanalysis identifies a novel CFAP54 variant in primary ciliary dyskinesia

Li et al., Frontiers in Medicine, 2025

Summary

  • Identifies a new likely pathogenic CFAP54 variant.

  • Expands the phenotypic spectrum of Primary Ciliary Dyskinesia (PCD).

Relevance to aspergillosis

  • PCD → impaired mucociliary clearance → chronic infection, bronchiectasis, and secondary fungal disease.

  • ABPA and CPA are increasingly recognised in non-CF bronchiectasis populations.

Strength

  • Genotype–phenotype correlation strengthens diagnostic confidence.

Limitation

  • Aspergillosis not a primary focus, but highly relevant to long-term respiratory outcomes.

3. Haematology, malignancy & invasive aspergillosis

Mixed-Phenotype Acute Leukemia Transforming into AML-M4

Alhayek et al., Cureus, 2025

Summary

  • Case of evolving leukemia complicated by pancytopenia, invasive pulmonary aspergillosis (IPA), and COVID-19.

Key points

  • Illustrates real-world stacked risk:

    • Neutropenia

    • Chemotherapy

    • Viral infection

    • IPA

Clinical relevance

  • Strong reminder that IPA often emerges during diagnostic or therapeutic transitions, not just during induction chemotherapy.

Invasive fungal infections in haematologic diseases: evidence, challenges, and practice

Cho et al., Blood Research, 2025 – Review

Summary

  • Comprehensive overview of invasive aspergillosis, candidiasis, and mucormycosis.

  • Covers diagnostics, antifungal resistance, and treatment strategies.

Strengths

  • Practical, guideline-aligned.

  • Emphasises individualised risk assessment and early treatment.

Gap

  • Limited discussion of long-term survivors and post-IPA chronic complications (e.g. CPA).

4. Imaging & diagnostics

CT Pulmonary Angiography in invasive pulmonary aspergillosis

Tian, Future Microbiology, 2025

Summary

  • Explores the role of CT pulmonary angiography (CTPA) in detecting angioinvasion.

Why it matters

  • Vascular occlusion and infarction are hallmarks of IPA.

  • CTPA may improve diagnostic confidence when standard CT is equivocal.

Limitations

  • Case-based evidence.

  • Needs integration into diagnostic algorithms.

Sequential serum galactomannan as an outcome marker

Többen et al., Int J Infect Dis, 2025

Summary

  • Registry-based exploratory analysis of serial galactomannan (GM).

Key finding

  • Trends in GM may correlate with treatment response, not just diagnosis.

Clinical importance

  • Supports GM as a monitoring biomarker, though interpretation remains complex.

Caution

  • Not reliable in all patient groups (e.g. non-neutropenic, antifungal pre-exposure).

5. Chronic pulmonary aspergillosis & structural disease

Molecular epidemiology of Aspergillus species in CPA (South India)

Spruijtenburg et al., Medical Mycology, 2025

Summary

  • Describes species diversity and genetic variation in CPA patients.

Why it matters

  • Highlights:

    • Geographic variation

    • Potential antifungal resistance implications

  • Supports species-level identification in CPA.

Strength

  • Strong laboratory–clinical interface.

Advanced pulmonary sarcoidosis

Spagnolo et al., Seminars in Respiratory and Critical Care Medicine, 2025

Summary

  • Reviews complications of advanced sarcoidosis, including:

    • Bronchiectasis

    • Pulmonary hypertension

    • Chronic pulmonary aspergillosis

Key point

  • CPA should be actively considered, not viewed as rare, in fibrotic sarcoidosis.

Rezafungin OPAT for chronic pulmonary aspergillosis

Law et al., JAC Antimicrobial Resistance, 2025

Summary

  • First real-world case of rezafungin used via outpatient parenteral therapy for CPA.

  • Includes a health-economic assessment.

Why this is important

  • CPA treatment options are limited.

  • Weekly dosing may:

    • Reduce hospital burden

    • Improve quality of life

Caution

  • Single case; echinocandins are not standard CPA therapy.

  • Best viewed as salvage or niche use.

6. Tracheobronchial & atypical aspergillosis

Tracheobronchial Aspergillosis Mimicking Pseudotumour

Castillo Gamboa et al., Clinical Case Reports, 2025

Summary

  • Rare presentation of tracheobronchial aspergillosis masquerading as malignancy.

Clinical lesson

  • Endobronchial disease can be missed or mislabelled.

  • Supports biopsy and fungal testing when appearances are atypical.

7. Immunology, inflammation & host–pathogen interaction

PANoptosis in pathogen infection and systemic disease

Cai et al., Cell Biology and Toxicology, 2025 – Review

Summary

  • Reviews PANoptosis (pyroptosis, apoptosis, necroptosis) in infections.

Relevance

  • Aspergillus is discussed as a trigger of complex inflammatory cell death pathways.

  • May help explain:

    • Severe tissue damage

    • Dysregulated inflammation in IPA

Translational value

  • Still mechanistic; clinical applications remain distant.

PD-1 / PD-L1 immune checkpoint in fungal infections

Zheng et al., Virulence, 2025 – Review

Summary

  • Explores immune exhaustion in ABPA, CPA, and IPA.

Key insight

  • Checkpoint pathways may:

    • Contribute to chronic infection persistence

    • Become future adjunctive immunotherapies

Important caution

  • Immune checkpoint modulation carries significant risk in fungal disease.

8. Antimicrobial stewardship & prophylaxis

Procalcitonin-guided antibiotics in RSV and influenza

Hessels et al., BMJ Open Respiratory Research, 2025

Finding

  • Reduced antibiotic use without increased fungal infection risk.

Relevance

  • Important reassurance that stewardship does not increase IPA risk in viral respiratory infections.

Letermovir prophylaxis post-HSCT

Kimura et al., J Infect Chemother, 2025

Key result

  • Letermovir did not increase invasive aspergillosis or candidemia risk.

Clinical reassurance

  • Supports ongoing antiviral prophylaxis strategies in transplant patients.

9. Experimental antifungals

Berberine suppresses Aspergillus fumigatus growth

Wang et al., ACS Infectious Diseases, 2025

Summary

  • Demonstrates antifungal activity via:

    • Mitochondrial fragmentation

    • Reactive oxygen species

    • Hog1-MAPK activation

  • Reduced fungal burden in a murine IPA model.

Important caution

  • Pre-clinical only.

  • Not a supplement recommendation for patients.

Overall themes & take-home messages

Key trends this week

  • Increasing recognition of rare immunodeficiency and genetic syndromes behind chronic lung disease.

  • Better understanding of non-classical aspergillosis presentations.

  • Strong interest in immune modulation, biomarkers, and novel therapies.

  • Continued need for early diagnosis, especially in haematology and advanced lung disease.

For clinical practice

  • Think beyond labels (asthma, CF, cancer).

  • Revisit diagnoses when disease behaves atypically.

  • CPA and ABPA remain under-recognised but increasingly documented across conditions.

If you’d like, I can:

  • Turn this into a NAC weekly research digest

  • Produce patient-safe summaries of selected papers

  • Extract figures and learning points for teaching or the Knowledge Hub

by GAtherton

🌍 THE MICROBIOME REVOLUTION

How gut and lung microbiota are transforming the way we diagnose, treat and understand infection in aspergillosis

https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41698-020-00138-z/MediaObjects/41698_2020_138_Fig1_HTML.png
https://www.cell.com/cms/10.1016/j.heliyon.2024.e24032/asset/c18ec70a-98da-43b9-8114-e20cf6cf2ab6/main.assets/gr3_lrg.jpg

For decades, infection was seen through a simple lens:

Find the organism → treat the organism → infection cured.

But modern microbiome research has shown that this view is too narrow—especially for chronic lung diseases such as aspergillosis, bronchiectasis, ABPA, SAFS and CPA.

We now understand that the:

  • lungs,

  • gut,

  • sinuses,

  • skin, and even

  • CPA cavities

contain complex microbial ecosystems (bacteria, fungi, viruses, archaea) that interact dynamically with each other and with your immune system.

Rather than being passive passengers, these microbes shape inflammation, immunity, symptoms, resistance, treatment response and overall wellbeing.

This is why microbiome science is truly revolutionising how clinicians think about infection.

🧬 1. What is a microbiome?

A microbiome is the entire community of microorganisms living in a particular environment, plus all the genes, chemicals, signals and interactions that exist between them.

Healthy microbiomes are:

  • diverse

  • stable

  • environmentally balanced

  • dominated by harmless or beneficial species

Disease-associated microbiomes are:

  • less diverse

  • unstable

  • dominated by a few harmful organisms

  • deeply involved in inflammation

This imbalance is called dysbiosis.

🫁 2. The lung microbiome: complex, dynamic, and vital

The lungs are not sterile—they contain a delicate, low-density microbiome.

In health, microbes drift in and out through:

  • breathing

  • micro-aspiration

  • mucociliary clearance

The “healthy lung microbiota” remains balanced because airflow and immune regulation prevent any single species from dominating.

In disease (aspergillosis, bronchiectasis, ABPA, SAFS, CPA), the situation changes:

  • thick mucus traps microbes

  • reduced airflow produces stagnant zones

  • inflammation increases microbial stickiness

  • biofilms form

  • pathogens dominate

  • microbial diversity drops

  • chronic inflammation becomes self-sustaining

This drives persistent symptoms even when cultures appear negative.

🍽️ 3. The gut microbiome: our “second immune system”

https://www.researchgate.net/publication/330336693/figure/fig3/AS%3A714099797270528%401547266067017/Proposed-schematic-representation-of-how-the-gut-microbiome-is-regulated-Risk-factors.jpg
https://www.researchgate.net/publication/326442483/figure/fig1/AS%3A11431281250325630%401717821322668/Interaction-between-gut-microbiota-and-immune-system-Gut-microbiota-metabolites-and.tif
https://pub.mdpi-res.com/cells/cells-13-01436/article_deploy/html/images/cells-13-01436-g001.png?1724759089=&utm_source=chatgpt.com

The gut contains trillions of bacteria, fungi and viruses.
Far from being limited to digestion, the gut microbiome influences:

  • immune development

  • inflammation control

  • IgE responses

  • eosinophils

  • energy levels

  • weight regulation

  • steroid responsiveness

  • susceptibility to infection

  • mental wellbeing

Up to 70% of your immune system is shaped by gut microbes.

This means:

Gut health directly affects lung health, including risk and severity of aspergillosis-related disease.

🔄 4. The Gut–Lung Axis: how the two microbiomes talk to each other

The gut and lungs are connected through a biochemical “highway” known as the gut–lung axis.

How the gut affects the lungs

Gut bacteria produce metabolites such as:

  • short-chain fatty acids (SCFAs) — e.g., butyrate

  • tryptophan metabolites

  • bile-acid derivatives

These travel in the bloodstream and regulate:

  • airway inflammation

  • Th2/Th17 immune responses

  • IgE and eosinophils

  • neutrophil activity

  • mucus production

  • tolerance to allergens (including fungal allergens)

  • steroid responsiveness

Low SCFA levels are linked to:

  • more severe asthma

  • worse fungal sensitisation

  • increased ABPA flares

  • poorer lung function

  • difficulty clearing infection

How lung disease affects the gut

Chronic respiratory disease increases:

  • gut permeability (“leaky gut”)

  • microbiota disruption

  • systemic inflammation

  • digestive symptoms

  • fatigue

  • candida overgrowth

Steroids and antibiotics worsen this further.

This creates a self-reinforcing circle of inflammation and dysbiosis.

🧱 5. Biofilms: microbial fortresses driving persistent disease

Biofilms are communities of microbes encased in a sticky protective matrix.

In aspergillosis and bronchiectasis, biofilms:

  • make organisms up to 100–1000× more resistant to treatment

  • protect microbes from the immune system

  • allow bacteria and fungi to communicate and collaborate

  • swap resistance genes

  • support mixed infections (e.g., Aspergillus + Pseudomonas)

  • cause chronic symptoms even with “negative” cultures

Biofilms also change the immune system’s behaviour, driving long-term inflammation.

🔬 6. What microbiome research has revealed so far

A. Infection is rarely a single organism

Microbiomes show that infections are polymicrobial ecosystems, not isolated pathogens.

B. Diversity = resilience

Higher microbial diversity is linked to:

  • better lung stability

  • fewer flare-ups

  • lower inflammation

Low diversity correlates with:

  • severe disease

  • CPA progression

  • ABPA flares

  • worse bronchiectasis outcomes

C. Microbiome patterns can predict future illness

Research shows that flare-ups often follow:

  • a drop in diversity

  • an increase in dominant pathogens

  • changes in fungal–bacterial interactions

D. Treatment responses are microbiome-dependent

The presence of certain bacteria can make Aspergillus:

  • grow faster

  • form stronger biofilms

  • resist antifungals

  • provoke more inflammation

🫁🌱 7. What patients can do to support their lung microbiota

Just as dietary fibre supports gut microbes, there are practical steps that support a healthier lung microbial ecosystem.

These steps do not introduce microbes into the lungs; instead, they improve the environment the microbiota lives in.

⭐ 1. Keep airways clear — the foundation of lung microbial health

Biofilms and harmful microbes thrive in stagnant mucus.

Effective clearance techniques:

  • Active Cycle of Breathing Techniques (ACBT)

  • Autogenic drainage

  • Oscillating devices (Flutter, Acapella, Aerobika)

  • Nebulised saline (3–7%)

  • Huffing and controlled coughing

Clearer airways → more airflow → better microbial balance.

⭐ 2. Hydration

Hydration thins mucus, improves ciliary function, and weakens biofilms.

⭐ 3. Use inhalers correctly & control inflammation

Inflamed, narrowed airways promote dysbiosis.

Good control of:

  • asthma

  • ABPA

  • eosinophilia
    reduces microbial imbalance.

⭐ 4. Improve sinus health

The sinuses drip microbes into the lungs all day long.

Sinus care (saline rinses, nasal steroids) supports lung microbiota stability.

⭐ 5. Avoid unnecessary antibiotics

Antibiotics disrupt:

  • lung microbiota

  • gut microbiota

  • fungal–bacterial balance

  • biofilm behaviour

Use them when needed — but avoid repeated unnecessary courses.

⭐ 6. Exercise

Exercise increases airflow and clearance, helping shift the lung microbiome toward a healthier, more diverse state.

⭐ 7. Reduce smoke and indoor pollutants

Pollutants:

  • paralyse cilia

  • thicken mucus

  • promote pathogenic microbes

  • reduce diversity

HEPA filtration, ventilation, and smoke avoidance all help.

⭐ 8. Manage reflux (GORD)

Micro-aspiration introduces stomach contents into the lungs, disrupting the lung microbiota.

Treating reflux supports lung microbial homeostasis.

⭐ 9. Support your gut microbiota

A healthy gut → more SCFAs → improved lung immunity → a more balanced lung microbiome.

Helpful for gut health:

  • fibre-rich foods

  • diverse diet

  • fermented foods (if tolerated)

  • avoiding unnecessary antibiotics

  • reducing alcohol

  • managing stress

🩺 8. What this means for the future of aspergillosis care

Within 5–10 years, we may routinely use:

  • microbiome sequencing in clinic

  • AI-designed “ecosystem maps” of the lungs

  • targeted therapies for mixed infections

  • inhaled agents that break down biofilms

  • gut-directed therapies to help lung disease

  • personalised airway clearance plans

  • microbial diversity scores to predict flares

This could:

  • reduce exacerbations

  • minimise antibiotic and antifungal exposure

  • improve quality of life

  • slow CPA progression

  • improve steroid responsiveness

  • reduce hospital admissions

🧠 9. Key takeaways

  • You have two important microbiomes that matter for aspergillosis:
    the lung microbiome and the gut microbiome.

  • They communicate through the gut–lung axis.

  • Dysbiosis (imbalance) increases inflammation and worsens fungal disease.

  • Biofilms make infections far more resistant and persistent.

  • Patients can support their lung microbiota through lifestyle steps, especially:

    • airway clearance

    • hydration

    • exercise

    • sinus care

    • avoiding unnecessary antibiotics

    • supporting gut health

  • Microbiome science is transforming future diagnosis and treatment strategies.

by GAtherton

Aspergillosis Research Highlights — Week in Review (Last 7 Days: Week 50)

Seven key publications: pathogenicity, diagnostics, resistance, treatment, maxillofacial disease, and ABPA in COPD.

1. Comparative Overview of A. fumigatus, A. flavus, and A. niger

Rafique et al., J Infect Public Health, 2025
DOI: 10.1016/j.jiph.2025.103070

What this adds

  • A major comparative review (2000–2025) of the three most clinically relevant Aspergillus species.

  • Highlights broad clinical spectrum: allergy → chronic disease → invasive aspergillosis.

  • Identifies species-specific concerns:

    • A. fumigatus: globally dominant, rapidly evolving triazole resistance.

    • A. flavus: important in warmer climates; high aflatoxin relevance.

    • A. niger: relatively lower virulence but significant in sinus disease.

  • Public health message: surveillance gaps persist, especially for non-fumigatus species.

Why it matters

A strong reference paper supporting the WHO prioritisation of Aspergillus, and reinforcing the need for:

  • Better diagnostics

  • Species-level identification

  • Environmental resistance monitoring

2. GFP Fusion Protein Proteolysis in A. fumigatus

Paul & Moye-Rowley, G3 (Bethesda), 2025
DOI: 10.1093/g3journal/jkaf295

What this adds

  • Fundamental molecular biology study revealing regulated degradation pathways of green fluorescent protein (GFP) fusion proteins inside A. fumigatus.

  • Demonstrates how the fungus controls protein turnover under stress conditions.

Why it matters

  • Advances tools for fungal cell biology.

  • Supports drug development by clarifying pathways involved in stress response and antifungal tolerance.

  • Reinforces WHO’s classification of A. fumigatus as one of the four most critical fungi to study.

3. ABPA in COPD: Case Series + Review

Ren et al., BMC Pulmonary Medicine, 2025
DOI: 10.1186/s12890-025-04027-8

What this adds

  • 11 COPD cases with confirmed Allergic Bronchopulmonary Aspergillosis — highlighting:

    • Under-recognition in COPD

    • Overlap with chronic bronchitis/bronchiectasis symptoms

    • Frequent misdiagnosis as recurrent infections or COPD exacerbations

  • Provides diagnostic guidance and a literature synthesis.

Why it matters

  • Significant implications for case finding across the UK.

  • Supports NAC messaging: ABPA is not only an asthma disease.

  • Reinforces need for:

    • IgE/IgG screening

    • Early CT imaging

    • Awareness among COPD teams and primary care

4. EL219: Next-Generation Polyene Antifungal

Youssef et al., AAC, 2025
DOI: 10.1128/aac.01400-25

What this adds

  • Animal model evidence that EL219, a modern polyene, is effective against:

    • Triazole-susceptible A. fumigatus

    • Azole-resistant isolates

    • Difficult species (A. lentulus, A. calidoustus)

Why it matters

  • Highly relevant to rising global antifungal resistance.

  • Early indication that EL219 may fill a clinical gap similar to (or complementary to) olorofim and fosmanogepix.

  • Suggests strong activity even in immunosuppressed models.

5. Misidentification & Triazole Resistance in Aspergillus tubingensis

Wang et al., JAMA Network Open, 2025
DOI: 10.1001/jamanetworkopen.2025.43630

What this adds

  • Large Southern California population study showing:

    • Frequent misidentification of A. tubingensis as A. niger.

    • Notable azole resistance rates in correctly identified isolates.

  • Stresses need for genomic sequencing or MALDI-TOF with updated libraries.

Why it matters

  • Strong evidence that misidentification leads to:

    • Inappropriate antifungal therapy

    • Poor outcomes

  • Supports calls for expanded diagnostic reference services such as MRCM.

6. 50-Year Review of Oral Fungal Infections in Thailand

Kosanwat et al., Clinical Oral Investigations, 2025
DOI: 10.1007/s00784-025-06685-8

What this adds

  • Longitudinal study: 29% of deep infections involved aspergillosis.

  • Mean age 62 → older adults most affected.

  • Many cases were mucormycosis, histoplasmosis, or aspergillosis presenting late.

Why it matters

  • Shows that oral/maxillofacial fungal disease remains under-recognised globally.

  • Relevant to dental teams → better imaging + biopsy protocols needed.

  • May help NAC/CARES identify referral pathways from dental medicine.

7. Management of Maxillary Sinus Aspergillosis with Implants

Khoury et al., Int J Oral Implantol, 2025

What this adds

  • Real-world 3–10 year follow-up of 11 patients.

  • Standardised approach:

    • Surgical clearance

    • Antifungal therapy

    • Successful implant-prosthetic rehabilitation

Why it matters

  • Demonstrates excellent long-term outcomes when sinus aspergillosis is properly treated.

  • Practical implications for:

    • ENT surgeons

    • Oral surgeons

    • Implant dentistry

  • Supports inclusion of aspergillosis in sinus disease differential diagnosis.

Cross-Cutting Themes Emerging This Week

1. Under-recognition and misidentification

  • ABPA in COPD

  • Misidentified A. tubingensis

  • Asymptomatic sinus disease

  • Oral/maxillofacial deep fungal infections

→ Key NAC message: We are missing cases in primary care, COPD clinics, ENT, and dentistry.

2. Antifungal resistance remains a central threat

  • Contemporary reviews of species-specific resistance patterns

  • EL219’s promise against resistant species

  • Misidentification leading to incorrect susceptibility assumptions

3. Need for better diagnostics and reference centres

  • Species-level identification is essential

  • Supports arguments for expansion of MRCM-style national services

4. The clinical spectrum is broad

From allergy (ABPA in COPD) → chronic sinus disease → deep oral infections → invasive pulmonary aspergillosis.
This reinforces the message: aspergillosis is multi-specialty, not confined to respiratory medicine.

Weekly NAC/MRCM Take-Home Messages

  • COPD teams should screen for ABPA more frequently—especially in patients with recurrent “infective exacerbations.”

  • Species-level identification is increasingly important; misidentification contributes to treatment failure.

  • New antifungals like EL219 show promise against resistant strains including A. lentulus.

  • Dental and ENT teams need better awareness: sinus and oral fungal infections remain overlooked but treatable.

  • Global reviews show growing public health significance of Aspergillus species—aligning with WHO priorities.

by GAtherton

Fungal Vaccines: What New Research Could Mean for Aspergillosis Patients

Based on the 2025 Journal of Clinical Investigation commentary on emerging fungal vaccine science

jci-135-199451

Why fungal vaccines matter

Fungal infections remain a major global health problem, causing an estimated 3.8 million deaths per year. Yet despite this huge burden, there are currently no licensed vaccines to prevent or treat fungal disease.

For people living with aspergillosis—including chronic pulmonary aspergillosis (CPA), allergic bronchopulmonary aspergillosis (ABPA), severe asthma with fungal sensitisation (SAFS), and Aspergillus bronchitis—this gap is very real.
Treatments often involve long-term antifungal medications, steroids, or biologics, and symptoms may recur despite therapy.

A new scientific commentary in the Journal of Clinical Investigation highlights major progress in fungal vaccine research and suggests that vaccines may become important tools for both prevention and treatment in the future.

A new breakthrough: the Eng2 fungal antigen

Researchers studying serious fungal infections in North and South America have identified an enzyme called endoglucanase-2 (Eng2) that triggers a strong immune response:

  • It protected mice from Blastomyces, Histoplasma, and Coccidioides infections.

  • People recovering from these infections show memory CD4 T-cell responses to Eng2.

This suggests two important possibilities:

1. A preventive vaccine

A future vaccine could reduce the risk of developing serious fungal infections—especially in people with weakened immune systems or chronic lung disease.

2. A therapeutic vaccine

Unlike most vaccines, a therapeutic vaccine would be given after infection to support the immune system and help clearance—similar to how post-exposure rabies or hepatitis A vaccines work.

This second application is particularly relevant to aspergillosis.

Why fungal vaccines may be especially useful in Aspergillus disease

Although the study did not focus on Aspergillus specifically, the commentary highlights several reasons why Aspergillus vaccines are scientifically realistic.

1. Fungi are surprisingly easy to vaccinate against in animal studies

Many fungal antigens have already shown strong protective effects in experimental models.

Unlike viruses such as HIV or tuberculosis—where vaccines are extremely difficult—fungal pathogens often respond well to:

  • Antibody-based immunity

  • T-cell immunity

Both would be valuable in Aspergillus-related disease.

2. Aspergillosis mainly affects people with weakened or inflamed lungs

This makes it exactly the kind of disease where a vaccine could:

  • Reduce fungal burden in the airways

  • Decrease inflammation

  • Support existing treatments

  • Reduce flare-ups and symptoms

3. A therapeutic vaccine may arrive before a preventive vaccine

Chronic fungal diseases (especially CPA and Aspergillus bronchitis) develop slowly and persist for months or years.
This gives time for a vaccine to stimulate the immune system during ongoing treatment.

A therapeutic vaccine could:

  • Enhance the effect of antifungal drugs

  • Reduce the amount of fungus growing in cavities or bronchiectatic airways

  • Lower inflammation and antibody levels

  • Potentially reduce the need for long-term steroids or biologics in ABPA

4. A combination (“multivalent”) vaccine is possible

The Eng2 research shows that one antigen may not protect against all fungal species.
However, a “cocktail” vaccine—using several fungal proteins—could cover multiple fungi, including Aspergillus.

What this could mean for different aspergillosis conditions

For CPA (Chronic Pulmonary Aspergillosis)

A therapeutic vaccine might help:

  • Reduce fungal load in cavities

  • Improve long-term control

  • Support patients who can’t tolerate antifungals

  • Reduce reliance on prolonged azole therapy

For ABPA (Allergic Bronchopulmonary Aspergillosis)

ABPA is an allergic reaction rather than a true infection.
But reducing the amount of Aspergillus in the airways could:

  • Decrease IgE levels

  • Reduce flare frequency

  • Lower the need for steroids

  • Improve asthma control

For SAFS and Aspergillus bronchitis

A vaccine could potentially:

  • Reduce airway colonisation

  • Improve symptom control

  • Reduce the cycle of infection → inflammation → airway damage

What this means for patients today

It is important to be clear:

There is no Aspergillus vaccine available yet.

However, the science is moving faster than ever.
The commentary highlights:

  • Multiple experimental vaccines have already worked in animals

  • Some fungal vaccines have reached early human trials

  • mRNA technology (used for COVID vaccines) could accelerate development

  • High-risk groups—including people with chronic lung disease—would be early candidates

For the aspergillosis community, this research is a major step forward, offering hope for safer and more effective long-term management.

For clinicians: why this matters now

Non-specialist clinicians may want to be aware that:

  • Vaccine-based immunotherapy may become part of fungal disease management

  • Therapeutic vaccines could work alongside antifungals, rather than replacing them

  • Advances in antigen identification (e.g., Eng2) create realistic pathways for Aspergillus-specific research

  • Patient groups with chronic fungal or allergic disease may benefit significantly from immunological boosting

As fungal disease continues to rise worldwide, vaccination represents a promising future tool in managing both invasive and chronic fungal illnesses.

Looking ahead

While fungal vaccines are “so needed, so feasible, and yet still far off,” the momentum is building.
For people living with aspergillosis—often for many years—the possibility of vaccines offers genuine hope for:

  • Better control

  • Improved quality of life

  • Reduced treatment burden

  • Less risk of long-term complications

This new research marks an important step on that journey.

by GAtherton

Could this new gene-therapy technology help aspergillosis patients?

Hunter syndrome stem cell treatment

Not directly now — but potentially yes in the longer term.

The gene therapy in the BBC story works because Hunter syndrome is caused by a single faulty gene. Doctors can take stem cells, insert a missing gene, and put them back into the body — and the body starts producing the enzyme that was missing.

Aspergillosis is different.
It isn’t caused by a single gene error — it’s caused by:

  • An over-reaction of the immune system in ABPA

  • Underlying lung damage or structural disease in CPA

  • A combination of genetics, environment, allergens and fungal exposure

  • Sometimes problems with mucus clearance

So gene therapy is not close to being used for aspergillosis in the same direct way.

But here’s why the technology could help in the future

The breakthrough still matters because it shows what is becoming possible:

1. Fixing immune-pathway problems

Some people with ABPA or severe asthma have genetic variants in pathways such as:

  • IL-4 / IL-5 / IgE regulation

  • Mucus clearance

  • Immune “switch-off” mechanisms

In the future, gene therapy could correct faulty immune pathways so the lungs stop over-reacting to Aspergillus.

2. Improving mucus-clearance biology

A big part of aspergillosis is mucus sticking in the airways. If gene therapy can one day boost the function of cilia or mucus-clearing enzymes, that would be a major benefit.

3. Helping people born with lung-structure problems

Some patients develop aspergillosis because they were born with subtle airway abnormalities or genetic bronchiectasis tendencies. Future gene therapies might stabilise or prevent these problems.

4. Fungal infection + rare-disease overlaps

Some immunodeficiency disorders (e.g., CARD9 deficiency) lead to severe fungal infections. This type of therapy is much closer to helping those patients already — because those are single-gene defects.

Realistic timeline

For ABPA or CPA specifically:

  • Short term (0–10 years): No direct gene therapy.

  • Medium term (10–20 years): Possible targeted immune-pathway correction for asthma/ABPA.

  • Long term (20+ years): Potential lung-repair gene therapies, airway-regeneration therapies, or personalised immune-modifying gene treatments.

So this breakthrough doesn’t change aspergillosis care today — but it shows that the tools are coming that could one day target immune-driven diseases much more precisely.

by GAtherton

⭐ Recent Aspergillosis Research & Guideline Updates (Week 47)

Several important new papers on aspergillosis, diagnosis, and antifungal therapy were published this week. These include updated UK guidance, new antifungal drug targets, and insights into diagnosing invasive disease in ICU settings.

1. British Society for Medical Mycology (BSMM) Best Practice Guidance

First author: Dr Rebecca Gorton
Institution: British Society for Medical Mycology (UK)
Published: Nov 2025
Focus: Diagnosis + antifungal stewardship + clinical scenarios

Summary

This newly updated best-practice article explains how clinicians should:

  • combine CT scans, IgG/IgE, PCR, and galactomannan

  • choose antifungals appropriately

  • avoid misdiagnosis

  • apply practical recommendations to real-world cases

It is one of the most up-to-date UK-relevant guidance documents.

Why this matters for patients

Better diagnosis → faster correct treatment → fewer unnecessary antifungals.

2. Diagnostic Algorithms for Invasive Aspergillosis in ICU Patients

First author: Dr Anne-Sophie Hartmann
Institution: University Hospital Freiburg, Germany
Published: Jun 2025
Focus: ICU diagnosis & emerging risk groups

Summary

This study shows that invasive aspergillosis is increasingly found in ICU patients, including those who do not have classic risk factors.
It tests new diagnostic “pathways” combining imaging and multiple laboratory markers.

Why this matters for patients

Improves early recognition of life-threatening fungal infections in critical illness.

3. Advances in Antifungal Drug Discovery (FK1 and new targets)

First author: Dr Jonathan Miles
Institution: University of Cambridge, UK
Published: Aug 2025
Focus: New drug targets & antifungal discovery

Summary

This review outlines progress in antifungal development, including:

  • Fungal Kinase 1 (FK1) as a new therapeutic target

  • new chemical classes

  • failings of older antifungals

  • the need for next-generation medicines

Why this matters for patients

Future antifungals may be more effective, safer, and active against resistant Aspergillus.

4. British Thoracic Society (BTS) Clinical Statement on Aspergillus Lung Disease

Lead author (Chair): Dr Elizabeth Sapey
Institution: University of Birmingham / British Thoracic Society
Published: May 2025
Focus: Chronic Aspergillus disease (CPA, ABPA, SAFS, Aspergillus bronchitis)

Summary

This statement sets out national guidance to improve diagnosis and management of chronic Aspergillus-related lung disease.
It supports earlier testing, consistent management, and clearer referral pathways.

Why this matters for patients

  • Better recognition of CPA and ABPA

  • Fairer access to specialist care

  • More consistent treatment across the UK

5. New Antifungal Drug Classes in Development (Rezafungin, Ibrexafungerp, Olorofim)

First author: Prof David Denning
Institution: University of Manchester / NAC
Published: Sep 2025
Focus: Emerging antifungal drugs

Summary

This review discusses the latest antifungal medicines in the pipeline:

  • Rezafungin – long-acting IV drug

  • Ibrexafungerp – new oral class

  • Olorofim – strong activity against resistant Aspergillus

It explains mechanisms of action, clinical trial progress, and potential future roles.

Why this matters for patients

New drugs are on the way to treat resistant and difficult Aspergillus infections.

📘 Summary Table (with authors & institutions)

Title/Topic Date First Author Institution Key Focus
BSMM Best Practice Nov 2025 Dr Rebecca Gorton British Society for Medical Mycology (UK) Diagnosis & stewardship
ICU Diagnostic Algorithms Jun 2025 Dr Anne-Sophie Hartmann University Hospital Freiburg, Germany ICU diagnosis
New Antifungal Drug Targets (FK1) Aug 2025 Dr Jonathan Miles University of Cambridge Drug discovery
BTS Clinical Statement May 2025 Dr Elizabeth Sapey University of Birmingham / BTS Chronic Aspergillus disease
New Antifungal Classes (Rezafungin/Olorofim) Sep 2025 Prof David Denning University of Manchester / NAC New drug development

💬 Overall Takeaway for Patients

Recent publications show strong progress:

  • Diagnosis is improving, especially in ICU and chronic disease clinics.

  • New antifungals are progressing, including drugs designed specifically to address resistance.

  • UK-specific guidance is strengthening, helping ensure more consistent, high-quality treatment for ABPA, CPA, SAFS, and Aspergillus bronchitis.

This is a period of rapid advancement in aspergillosis care, and the findings highlighted here directly support better outcomes for patients.

by GAtherton

ECFG 2025: Key Aspergillus and Antifungal Insights for Patients and Clinicians

The European Conference on Fungal Genetics (ECFG 2025) gathered the leading fungal biology teams from across the world. Although primarily a genetics meeting, several abstracts offered direct clinical relevance for people living with aspergillosis or those working in the field.

The research covered here focuses on:

  • Aspergillus fumigatus

  • mechanisms of disease

  • resistance to antifungals

  • emerging antifungal treatments

  • environmental drivers of disease

  • insights relevant to CPA, ABPA, SAFS, bronchiectasis and invasive aspergillosis

Summary of Key Themes

1. Aspergillus genetic diversity is much greater than assumed

Pangenome work showed A. fumigatus strains possess different virulence genes and resistance traits. This may explain differences in how patients respond to infection and medication.

2. Environmental azole resistance continues to rise

Multiple abstracts confirmed that resistant strips often originate outdoors, shaped by climate, fungicides, soil chemistry, and climate change.

3. Promising new antifungals are advancing

Manogepix shows excellent activity against resistant strains, while several early-stage compounds (such as G-quadruplex ligands) represent brand-new modes of action.

4. Insights into virulence, persistence and treatment failure

Studies on hyphal fusion, echinocandin tolerance, and hypoxia adaptation shed light on chronic and resistant infections.

5. Improved tools accelerate antifungal discovery

CRISPR and genus-wide sequencing speed up the search for new drug targets and better diagnostics.

ECFG 2025 — Table of All Aspergillus / Aspergillosis / Antifungal-Relevant Abstracts

ID Title Lead Author / Presenter Institution Category Why It Matters
WS1.19 Reference pangenomes for A. fumigatus Marion Perrier Friedrich Schiller University, Jena Genomics / Evolution Reveals hidden genetic diversity linked to virulence and resistance.
WS1.20 Antifungal modes of action of G-quadruplex ligands Isabelle Storer University of East Anglia New antifungal mechanisms Suggests a brand-new antifungal class targeting fungal DNA structures.
WP1.2 NL1 as anti-virulence compound Jorge Amich ISCIII, Spain Virulence / Therapeutics May reduce disease severity without relying on killing the fungus.
WP1.6 Ace2 and RAM pathway regulation Devi N. J. Bale — Pathogenesis Controls tissue invasion, morphology and possibly drug sensitivity.
WP1.8 Hyphal fusion and multi-drug resistant heterokaryons Michael Bottery University of Manchester Resistance mechanisms Shows resistance traits may spread between strains via fusion.
WP1.10 Manogepix activity against A. fumigatus Sean Brazil Trinity College Dublin New antifungals Strong activity including against resistant strains and biofilms.
WP1.14 ZfpA and echinocandin tolerance Dante Calise University of Wisconsin Echinocandin tolerance Explains how fungi sometimes survive caspofungin and related drugs.
WP1.16 Genetic background of azole-resistant A. fumigatus Saioa Cendón-Sánchez University of the Basque Country Environmental resistance Confirms resistant genotypes circulate between the environment and patients.
WP1.18 Genus-wide sequencing of Aspergillus Ronald P. de Vries Westerdijk Institute Evolution / Pathogenicity Identifies traits making some species pathogenic to humans.
WP1.22 Climate, soil & fungicide impacts on Aspergillus Thomas Easter University of Manchester Environmental epidemiology Links climate change and fungicides to rising azole resistance.
WP1.32 Multiplex CRISPR to accelerate antifungal research Fabio Gsaller — Research tools Speeds identification of resistance pathways and drug targets.
WP1.42 Hypoxia-driven adaptations in A. fumigatus Olaf Kniemeyer — Pathogenesis Explains persistence of A. fumigatus in low-oxygen lung cavities (CPA).

Detailed Clinical Relevance of the Findings

1. Rising environmental resistance

Azole-resistant A. fumigatus continues to emerge in agricultural and urban settings. Resistant spores are carried in air and soil, meaning people inhale them in daily life. This is especially relevant to those with CPA, ABPA, bronchiectasis and immunosuppression, who are more vulnerable.

Why it matters:
Resistant strains are a growing cause of treatment failure.

2. New antifungal treatments are progressing

Manogepix shows potent activity against resistant Aspergillus and biofilms, key in difficult-to-treat CPA and invasive aspergillosis.

G-quadruplex ligands and NL1 represent early steps toward new antifungal classes, extremely important after two decades of limited drug options.

3. Virulence and survival mechanisms explain persistent disease

Hypoxia adaptation (low-oxygen survival) helps explain why Aspergillus persists in lung cavities.
Hyphal fusion may allow rapid spread of resistance traits.
Echinocandin tolerance mechanisms (ZfpA) reveal why some invasive cases fail to respond.

Why it matters:
These insights help clinicians anticipate treatment difficulties and inform research for new therapies.

4. Better genomic tools support faster discovery

Multiplex CRISPR and pangenomic databases allow scientists to uncover gene functions much faster. This shortens the path to new antifungal development and improves understanding of how resistance evolves.

Conclusion

ECFG 2025 provides important clues about why Aspergillus disease is so persistent, why azole resistance is increasing, and how new antifungal drugs may overcome today’s challenges. It also reinforces that environmental drivers — including fungicide use and climate factors — are a major part of the problem.

For patients, clinicians, and researchers, these findings highlight a rapidly evolving landscape in aspergillosis research, with promising signs of future treatment improvements.

by GAtherton

TIMM 2025 – Aspergillosis-Relevant Highlights for Non-Specialist Professionals

BRIEFING: Key Aspergillosis Themes from TIMM 2025

(For non-specialist professionals and patient advocates)

The 2025 TIMM abstracts show continuing concern around rising azole resistance, emerging Aspergillus species, and ongoing diagnostic challenges in chronic and invasive disease. A growing number of studies highlight the importance of environmental surveillance, molecular diagnostics, and recognising less typical at-risk groups such as people with viral pneumonias, COPD, and those receiving new biologics or immunomodulators.

Clinical messages for non-specialists:

1. Environmental and agricultural azole use remains a major resistance driver

Multiple studies (Latin America, Spain, Belgium) confirm that agricultural triazoles continue to select for resistant Aspergillus fumigatus. Resistant strains do reach hospital environments, including ICUs and haematology wards.

Implication:
Healthcare teams must remain alert to azole treatment failure, consider susceptibility testing, and recognise that resistance is no longer rare.

2. Cryptic and emerging Aspergillus species are increasingly recognised

Traditional diagnostics often miss less common species such as A. turcosus, A. hiratsukae, and A. pseudodeflectus.
MALDI-TOF may misidentify these species; molecular sequencing gives clearer answers.

Implication:
If disease progresses unexpectedly or does not respond to standard therapy, consider the possibility of an unusual Aspergillus species.

3. New risk groups for invasive aspergillosis

Studies from Europe highlight increasing cases of IA in:

  • Severe viral pneumonia (RSV, influenza, COVID-19)

  • Patients receiving modern biologics (tocilizumab, oblituzumab)

  • Children with haematological cancers

  • Lung transplant recipients (with late-onset IA)

  • COPD patients or those without classical immunosuppression

Implication:
Non-specialists should be aware that IA is no longer confined to neutropenia or transplant; clinicians should maintain suspicion in severely unwell respiratory patients.

4. Diagnostic testing improves when multiple methods are combined

Several abstracts show:

  • Combining galactomannan + PCR on BAL substantially improves detection.

  • Western blot + IgE/IgG pairing improves ABPA and CPA diagnosis.

  • ICAP alone has a very high false-positive rate.

Implication:
Do not rely on a single test. ABPA and CPA particularly require combined clinical + radiological + serological evidence.

5. Aspergillus biofilms remain important and difficult to treat

Biofilm studies show that:

  • Mature Aspergillus biofilms are highly drug-tolerant.

  • Co-habiting bacteria (e.g., Stenotrophomonas maltophilia) enhance biofilm stability.

  • Biofilms may explain chronic, relapsing airways disease patterns in CPA/ABPA/bronchiectasis patients.

Implication:
Patients with chronic or relapsing symptoms may have biofilm-driven inflammation and reduced antifungal penetration.

6. Mortality in invasive disease remains high

Reports from transplant units and paediatric oncology centres show:

  • 58% mortality in paediatric invasive aspergillosis.

  • 6% IA-related mortality in lung transplant cohort (with many later indirect deaths).

  • Early diagnosis and correct drug choice remain critical.

Implication:
Prompt recognition and appropriate antifungal selection (including combination therapy when needed) remain essential.

TABLE OF ALL RELEVANT ASPERGILLUS / ASPERGILLOSIS / ANTIFUNGAL ABSTRACTS

(From full-document review; includes resistance, diagnostics, epidemiology, biofilms, and case reports)

ID Title / Topic Type
Latin America Environment Study Environmental azole resistance across 12 countries; 2152 A. fumigatus isolates Environmental / Resistance
P026 A. fumigatus in Belgian hospitals: triazole resistance surveillance Environmental / Clinical resistance
27-Year Spain Study (Ashraph et al.) 118 azole-resistant strains; multiple fungicide resistance mechanisms Environmental / Genomics / Resistance
P317 Invasive sinus aspergillosis by A. hiratsukae in transplant recipient Case report / Cryptic species
CPA Case – A. pseudodeflectus Chronic necrotising CPA from rare Usti-section Aspergillus CPA / Case
P389 Metagenomics confirming mixed Aspergillus infection (A. niger + A. terreus) Diagnostics / Mixed infection
A. turcosus fatal IA case Cryptic fumigati species causing fatal invasive infection Case report / Cryptic species
P213 Difficult CPA diagnosis in COPD CPA / Clinical
P224 Recurrent maxillary sinus aspergilloma with bone destruction Sinus aspergillosis
P267 Epidemiology of Aspergillus-related lung disease (IPA, CPA, ABPA) in Marseille Epidemiology
P252 Species distribution in 418 filamentous fungal infections – Aspergillus dominant Epidemiology
Lung transplant cohort (1100 pts) IPA incidence, risk factors, treatment outcomes IPA / Transplant
Paediatric oncology IA cohort 43 cases; high mortality Paediatric IA
P352 RSV-associated invasive pulmonary aspergillosis Viral-associated IPA
Asp-WB + ICAP combination study Improved diagnosis of ABPA/CPA; ICAP alone widely false positive Diagnostics
Molecular vs GM vs culture study PCR on BAL highly accurate for Aspergillus detection Diagnostics
P154 Lateral flow assay (LFA) for Aspergillus in sputum/serum Diagnostics
Mixed biofilm GAG study Bacterial–fungal synergy increases biofilm resilience Biofilms / Pathogenesis
P090 Aspergillus biofilm extracellular matrix across strains and mixed species Biofilms
TB–fungal co-infection (Aspergillus rare but present) 7 Aspergillus co-infections among TB cohort Epidemiology

TABLE OF ALL RELEVANT ASPERGILLUS / ASPERGILLOSIS / ANTIFUNGAL ABSTRACTS WITH SUMMARIES

ENVIRONMENTAL & RESISTANCE STUDIES

1. Latin America Environmental Study

Topic: Air sampling in 12 countries: azole-resistant A. fumigatus widely present.
Summary: Large-scale citizen-science sampling found resistant Aspergillus spores across cities, rural sites, and farms. Confirms that humans inhale resistant strains from the environment, not just healthcare settings.

2. P026 — A. fumigatus in Belgian Hospitals

Topic: Hospital environmental surveillance for triazole resistance.
Summary: Resistant strains were found inside clinical areas, indicating they can enter hospitals via outdoor air. Important for infection control planning and for selecting appropriate antifungal therapy.

3. 27-Year Spanish Resistance Evolution Study (Ashraph et al.)

Topic: 118 azole-resistant isolates characterised over nearly three decades.
Summary: Shows a clear link between agricultural fungicide exposure and clinical resistance. Some strains developed multi-fungicide resistance, not just medical azoles.

CLINICAL CASES & CRYPTIC SPECIES

4. P317 — A. hiratsukae Sinusitis in Transplant Patient

Topic: Rare Aspergillus species causing invasive sinus disease.
Summary: Standard tests misidentified the fungus. Molecular sequencing confirmed a rare species. Highlights the need for advanced diagnostics when patients fail to improve.

5. CPA Case — A. pseudodeflectus

Topic: Chronic pulmonary aspergillosis caused by an unusual species.
Summary: Routine ID methods mislabelled the organism. Demonstrates cryptic species can cause CPA and may have different antifungal patterns.

6. Mixed A. niger + A. terreus Wound Infection (Metagenomics)

Topic: Mixed Aspergillus infection detected only by sequencing.
Summary: Traditional culture missed the second species. Mixed infections may explain poor responses to treatment.

7. A. turcosus Fatal IA Case

Topic: Rare fumigati section species.
Summary: Standard MALDI-TOF misidentified the species. High mortality emphasises why correct species identification matters for appropriate antifungal choice.

8. P213 — CPA Misdiagnosed as COPD

Topic: Chronic necrotising CPA mimicking COPD exacerbations.
Summary: Symptoms and imaging resembled COPD flare-ups. Only biopsy and molecular tests confirmed CPA. Highlights need for fungal testing in patients with atypical COPD.

9. P224 — Recurrent Maxillary Sinus Aspergilloma

Topic: Aspergillus sinus infection with bone involvement.
Summary: Shows how aspergilloma can recur if fungal debris remains or anatomy predisposes to blockage. ENT review and sometimes surgery are essential.

EPIDEMIOLOGY & COHORT STUDIES

10. P267 — Aspergillus Lung Disease in Marseille

Topic: Mix of ABPA, CPA and IPA.
Summary: Many ABPA cases were untreated or misclassified. Underlines widespread under-diagnosis and need for education of clinicians.

11. P252 — Species Distribution in 418 Fungal Infections

Topic: Large clinical review of filamentous fungi.
Summary: Aspergillus was the most common mould isolated, with A. fumigatus dominating. Confirms its continuing role as the most clinically significant mould.

12. Lung Transplant Cohort (1100 patients)

Topic: IA incidence, timing, species distribution and outcomes.
Summary: Early IA occurred from colonisation or environmental exposure; late IA linked to rejection and immunosuppression. Mortality remains high.

13. Paediatric Oncology IA Cohort

Topic: 43 children with invasive aspergillosis.
Summary: Mortality 58%. Mostly in acute leukemias. Underscores need for rapid testing and early therapy in children.

14. P352 — RSV-Associated Invasive Aspergillosis

Topic: Expanding “viral-associated pulmonary aspergillosis” beyond influenza and COVID-19.
Summary: RSV can also predispose immune-competent patients to IA. Important emerging risk category.

DIAGNOSTICS

15. Asp-Western Blot + IgE/IgG Combination Study

Topic: Diagnostic accuracy for ABPA/CPA.
Summary: Combining tests improves accuracy. ICAP alone is unreliable, with high false positives.

16. Molecular vs GM vs Culture Study (Italy)

Topic: Diagnostic accuracy of PCR on BAL.
Summary: PCR in BAL fluid was the most sensitive method. Combining PCR + galactomannan gave the best results.

17. P154 — Lateral Flow Assay (LFA)

Topic: Rapid point-of-care test for Aspergillus antigen.
Summary: Good performance in pre-treated sputum and serum. Promising as a rapid triage tool.

BIOFILM & PATHOGENESIS

18. Mixed Biofilm Study — A. fumigatus + S. maltophilia

Topic: How fungi and bacteria form stabilised mixed biofilms.
Summary: The Aspergillus biofilm sugar GAG enhances bacterial adhesion. Explains why some patients have stubborn, relapsing infections.

19. P090 — Biofilm Extracellular Matrix Study

Topic: Differences in matrix structure across Aspergillus strains.
Summary: Certain strains form thicker, more drug-resistant biofilms. May explain different patient responses to the same antifungal treatment.

TB CO-INFECTION (Aspergillus-related)

20. TB + Fungal Co-infection Study

Topic: TB patients screened for fungal disease.
Summary: Aspergillus infections were rare but present. Highlights need to consider CPA in chronic post-TB lung damage.

by GAtherton